Patents by Inventor Pamela S. Nuccitelli

Pamela S. Nuccitelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10391125
    Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 27, 2019
    Assignee: PULSE BIOSCIENCES, INC.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20190022141
    Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.
    Type: Application
    Filed: September 26, 2018
    Publication date: January 24, 2019
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Patent number: 10137152
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: November 27, 2018
    Assignee: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20180153937
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Application
    Filed: January 17, 2018
    Publication date: June 7, 2018
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Publication number: 20170333112
    Abstract: An optimization of electrical characteristics for treatments of tumor or other abnormal cells in culture with sub-microsecond, high-electric field electrical pulses is disclosed. The voltages, pulse widths, and number of pulses are chosen such that the treatment energy is 10-20 J/mL. That is, U=n*?t*V*I/volume is 10-20 J/mL, in which n is the number of pulses, ?t is the duration of each pulse, V is the voltage, I is current, and volume is the area of parallel electrodes times the distance between them. V divided by the distance between the electrodes can be in an effective range of 6 kV/cm to 30 kV/cm, 60 kV/cm, 100 kV/cm, or higher intensities. Rows of needle electrodes, blade electrodes, or other configurations of electrodes can approximate parallel electrodes.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard L. Nuccitelli, Zachary R. Mallon, Amanda H. McDaniel, David J. Danitz, Brian G. Athos, Mark P. Kreis, Darrin R. Uecker, Pamela S. Nuccitelli
  • Publication number: 20170216353
    Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Applicant: Pulse Biosciences, Inc.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge